Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index

OBJECTIVE: To investigate the impact of baseline and time‐varying factors on the risk of serious adverse events (SAEs) in patients during long‐term certolizumab pegol (CZP) treatment. METHODS: Safety data were pooled across 34 CZP clinical trials in rheumatoid arthritis (RA), axial spondyloarthritis...

Descripción completa

Detalles Bibliográficos
Autores principales: Bykerk, Vivian P., Blauvelt, Andrew, Curtis, Jeffrey R., Gaujoux‐Viala, Cécile, Kvien, Tore K., Winthrop, Kevin, Tilt, Nicola, Popova, Christina, Mariette, Xavier, Haraoui, Boulos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363853/
https://www.ncbi.nlm.nih.gov/pubmed/34196507
http://dx.doi.org/10.1002/acr2.11259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363853/
https://www.ncbi.nlm.nih.gov/pubmed/34196507
http://dx.doi.org/10.1002/acr2.11259

Ejemplares similares